Biogen Inc. (BIIB) is a leading biotechnology company focused on discovering, developing, and delivering therapies for ...

While Biogen Inc.'s BIIB base business is declining, it is entering a period of pipeline optionality, with eight Phase III ...

Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing ...

Biogen has won U.S. Food and Drug Administration breakthrough-therapy designation for its proposed salanersen treatment for the neuromuscular disease spinal muscular atrophy, or SMA. The Cambridge, ...

Biogen ( (BIIB)) has issued an announcement. On June 9, 2026, Biogen Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected ten directors, including CEO Christopher A.

Biogen has agreed to pay $18.9 million to resolve a lawsuit alleging that it misled investors about the commercial readiness ...

In early June 2026, Biogen reported that the FDA granted Breakthrough Therapy Designation to its investigational SMA treatment salanersen, while also, alongside UCB, presenting additional positive ...

Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene ...

View Biogen Inc. BIIB stock quote prices, financial information, real-time forecasts, and company news from CNN.

Biogen announced it will buy Human Immunology Biosciences (HI-Bio) in a deal worth up to $1.8 billion Wednesday morning. Per terms of the transaction, Biogen will make an upfront payment of $1.15 ...

Biogen reported first-quarter profit that topped estimates as the company's cost-cutting efforts took hold and sales of its closely watched Alzheimer's drug, Leqembi, came in higher than expected.

Apellis Pharmaceuticals Inc. shareholders who sued the drugmaker’s leadership for allegedly concealing the safety risks of a blindness-prevention drug are dropping their suit following Biogen Inc.'s ...